MARKET

PVCT

PVCT

Provectus Biopha
OTCMQB

Real-time Quotes | Nasdaq Last Sale

0.060
+0.005
+8.18%
Closed 13:38 05/18 EDT
OPEN
0.060
PREV CLOSE
0.055
HIGH
0.060
LOW
0.060
VOLUME
10.00K
TURNOVER
595
52 WEEK HIGH
0.078
52 WEEK LOW
0.042
MARKET CAP
24.96M
P/E (TTM)
-3.9933
1D
5D
1M
3M
1Y
5Y
Provectus to get US patent for topical PH-10 to treat certain skin conditions
Provectus (OTC:PVCT) said the U.S. Patent and Trademark Office (USPTO) allowed a patent application covering the use of topical PH-10 to treat certain inflammatory skin conditions. The company said the U.S. patent
Seekingalpha · 05/03 10:42
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of PH-10 Immuno-Dermatology Agent for Treatment of Inflammatory Dermatoses and Epithelial Diseases
KNOXVILLE, TN, May 03, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/204,832, “Combination of local and systemic therapies for enhanced...
GlobeNewswire · 05/03 10:00
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
KNOXVILLE, TN, April 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10, a formulation of Provectus’ immunogenic-small molecule and pharmaceutical-grad...
GlobeNewswire · 04/27 14:00
Provectus to get US patent for PV-10 to treat hematologic diseases
Provectus (OTC:PVCT) said the U.S. Patent and Trademark Office (USPTO) allowed a patent application covering the use of PV-10 to treat hematologic diseases. The company said the U.S. patent application 16/688,319
Seekingalpha · 04/26 12:26
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology
KNOXVILLE, TN, April 26, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/688,319, “Composition and Method for Treating Hematologic Cancers,” co...
GlobeNewswire · 04/26 11:30
Provectus Biopharmaceuticals Seeks Stockholder Approval at 2022 Annual Meeting for Authority to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
KNOXVILLE, TN, April 19, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that, in conjunction with the filing of the Company’s preliminary 2022 proxy statement (Pre-14A), Provectus’ Board of Directors (Board) seeks approvals at the Company...
GlobeNewswire · 04/19 20:00
BRIEF-Provectus Biopharma Names Aru Narendran To Scientific Advisory Board
reuters.com · 04/14 11:35
Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board
KNOXVILLE, TN, April 14, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Aru Narendran, MD, PhD to the Company’s Scientific Advisory Board. Dr. Narendran is a professor in the departments of Pediatrics, Oncology, and Bioche...
GlobeNewswire · 04/14 11:30
More
No Data
Learn about the latest financial forecast of PVCT. Analyze the recent business situations of Provectus Biopha through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
0.000.000.000.00
    0
Q3 2020
    0
Q4 2020
    0
Q1 2021
    0
Q2 2021
    0
Q3 2021
Institutional Holdings
Institutions: 4
Institutional Holdings: 130.60K
% Owned: 0.03%
Shares Outstanding: 419.45M
TypeInstitutionsShares
Increased
0
0
New
1
1
Decreased
0
0
Sold Out
1
22.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.25%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Chairman/Director
Edward Pershing
President
Timothy Scott
Vice Chairman/Director
Dominic Rodrigues
Chief Financial Officer
Heather Raines
Chief Operating Officer/Director
Bruce Horowitz
Chief Technology Officer
Eric Wachter
Director
Webster Bailey
Director
John Lacey
Director
Tim Lu
No Data
No Data
About PVCT
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

Webull offers kinds of Provectus Biopharmaceuticals Inc stock information, including OTCMQB:PVCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PVCT stock methods without spending real money on the virtual paper trading platform.